Joseph J Eron Selected Research

ogalvibart

1/2024

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joseph J Eron Research Topics

Disease

51	Acquired Immunodeficiency Syndrome (AIDS) 10/2023 - 02/2002
42	HIV Infections (HIV Infection) 03/2024 - 07/2002
41	Infections 05/2024 - 07/2002
39	COVID-19 05/2024 - 01/2021
28	Viremia 03/2024 - 11/2003
11	Neoplasms (Cancer) 03/2024 - 01/2013
11	Coinfection 01/2022 - 02/2006
9	Inflammation (Inflammations) 10/2022 - 05/2011
6	Cardiovascular Diseases (Cardiovascular Disease) 10/2023 - 08/2008
6	Myocardial Infarction 01/2023 - 05/2014
5	Disease Progression 05/2024 - 09/2002
5	Hepatitis B 01/2021 - 08/2008
5	Sepsis (Septicemia) 01/2021 - 01/2017
5	Hepatitis C 01/2019 - 04/2005
4	Injection Site Reaction 01/2024 - 12/2005
4	Hypertension (High Blood Pressure) 01/2022 - 07/2013
4	Substance-Related Disorders (Drug Abuse) 01/2020 - 02/2007
4	Lymphoma (Lymphomas) 07/2014 - 08/2012
3	Virus Diseases (Viral Diseases) 04/2024 - 12/2010
3	Persistent Infection 01/2022 - 09/2011
3	Chronic Renal Insufficiency 01/2022 - 09/2012
3	Marijuana Use 12/2021 - 01/2017
3	Obesity 01/2021 - 01/2016
3	Weight Gain 01/2021 - 01/2016
3	Fibrosis (Cirrhosis) 07/2015 - 01/2014
3	Tuberculosis (Tuberculoses) 05/2015 - 09/2011
3	Pneumonia (Pneumonitis) 01/2008 - 05/2003
2	Dyslipidemias (Dyslipidemia) 01/2022 - 07/2013
2	Ischemic Stroke 01/2021 - 01/2019
2	Overweight 01/2021 - 01/2016
2	Atherosclerotic Plaque (Atheroma) 01/2019 - 01/2017
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2016 - 06/2014
2	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2016 - 01/2013

Drug/Important Bio-Agent (IBA)

56	RNA (Ribonucleic Acid)IBA 01/2024 - 07/2002
26	Antiviral Agents (Antivirals)IBA 05/2024 - 06/2008
15	Monoclonal AntibodiesIBA 05/2024 - 11/2021
12	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 05/2010
12	Raltegravir Potassium FDA Link 10/2021 - 02/2010
11	Emtricitabine (Emtriva)FDA Link 11/2023 - 12/2011
10	Biomarkers (Surrogate Marker)IBA 03/2024 - 01/2013
10	Tenofovir (Viread)FDA Link 11/2023 - 12/2011
8	bamlanivimabIBA 11/2023 - 09/2021
7	Viral RNAIBA 05/2024 - 05/2010
7	efavirenz (Sustiva)FDA Link 10/2021 - 07/2014
6	Oxygen (Dioxygen)IBA 01/2023 - 01/2017
5	NucleosidesIBA 01/2022 - 07/2002
5	Ritonavir (Norvir)FDA Link 03/2015 - 01/2012
4	Broadly Neutralizing AntibodiesIBA 03/2024 - 09/2011
4	RacivirIBA 11/2023 - 01/2018
4	Opioid Analgesics (Opioids)IBA 01/2023 - 01/2017
4	Immunoglobulin G (IgG)IBA 01/2023 - 06/2021
4	Methamphetamine (Desoxyn)FDA LinkGeneric 01/2022 - 01/2017
4	AntibodiesIBA 01/2022 - 07/2009
4	Nucleic AcidsIBA 12/2021 - 07/2002
4	cabotegravirIBA 12/2021 - 10/2015
4	Cocaine (Cocaine HCl)IBA 01/2021 - 01/2017
3	nirmatrelvir and ritonavir drug combinationIBA 02/2024 - 08/2022
3	Vorinostat FDA Link 02/2024 - 01/2020
3	AntigensIBA 02/2024 - 01/2012
3	Proteins (Proteins, Gene)FDA Link 10/2023 - 12/2010
3	VaccinesIBA 01/2023 - 05/2010
3	Immunoglobulins (Immunoglobulin)IBA 01/2023 - 02/2009
3	Crack CocaineIBA 01/2022 - 01/2017
3	dolutegravirIBA 10/2021 - 03/2013
3	abacavir (Ziagen)FDA Link 01/2021 - 01/2002
3	Darunavir (Prezista)FDA Link 01/2021 - 08/2013
3	InterferonsIBA 11/2020 - 10/2014
3	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 01/2014
3	Atazanavir Sulfate (Reyataz)FDA Link 01/2019 - 01/2014
3	TabletsIBA 01/2019 - 01/2018
3	Reverse Transcriptase InhibitorsIBA 10/2015 - 04/2007
2	romlusevimabIBA 05/2024 - 01/2023
2	amubarvimabIBA 05/2024 - 01/2023
2	EpitopesIBA 11/2023 - 09/2006
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2023 - 12/2010
2	LipidsIBA 01/2023 - 10/2020
2	tixagevimabIBA 01/2023 - 12/2022
2	cilgavimabIBA 01/2023 - 12/2022
2	molnupiravirIBA 01/2022 - 06/2021
2	Immunoglobulin M (IgM)IBA 01/2022 - 06/2021
2	IntegrasesIBA 12/2021 - 01/2021
2	elvitegravirIBA 10/2021 - 12/2018
2	CobicistatIBA 10/2021 - 12/2018
2	Heroin (Diamorphine)IBA 01/2021 - 01/2017
2	Integrase InhibitorsIBA 01/2021 - 01/2020
2	Illicit Drugs (Recreational Drugs)IBA 01/2021 - 01/2017
2	cobicistat mixture with darunavirIBA 01/2019 - 01/2018
2	CreatinineIBA 01/2019 - 12/2018
2	BilirubinIBA 01/2019 - 01/2014
2	tenofovir alafenamideIBA 12/2018 - 01/2018
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 10/2018 - 07/2002
2	Rilpivirine (TMC-278)IBA 09/2017 - 10/2015
2	insulin receptor-related receptor (IRR)IBA 01/2016 - 01/2008

Therapy/Procedure

91	Therapeutics 05/2024 - 11/2003
34	Art Therapy 03/2024 - 08/2010
17	Highly Active Antiretroviral Therapy (HAART) 07/2015 - 02/2002
3	Injections 12/2021 - 10/2015
2	Aftercare (After-Treatment) 01/2023 - 01/2018
2	Critical Care (Surgical Intensive Care) 01/2022 - 10/2021
2	Immunotherapy 01/2020 - 01/2020